NeuroOne Joins Dartmouth NIH Grant to Develop Brain Sensing Tech
NeuroOne has joined a Dartmouth-led research team awarded a $1 million NIH grant to advance neurotransmitter sensing technology.
NeuroOne, a medical technology company, has been named a partner in a Dartmouth-led research consortium that secured a $1 million grant from the National Institutes of Health to develop advanced neurotransmitter sensing technology, according to an announcement released Wednesday.
The collaboration positions NeuroOne alongside academic researchers at Dartmouth to push forward innovations in detecting and measuring neurotransmitters — chemical messengers in the brain that play a central role in neurological and psychiatric conditions. Advances in this sensing technology could have broad implications for the diagnosis and treatment of disorders ranging from Parkinson's disease to depression.
Read more Voltus Secures $225M to Expand Grid Flexibility to 20 GW by 2030 →
For NeuroOne, participation in a federally funded research program of this scale represents a significant step in validating its neurotechnology platform. NIH-backed grants typically signal peer-reviewed scientific credibility and can serve as a springboard for further private investment or regulatory advancement.
The $1 million award reflects continued federal investment in neuroscience infrastructure, an area that has drawn growing attention as the medical community seeks more precise tools for understanding brain chemistry in real time. Dartmouth's role as lead institution suggests the university's neuroscience and engineering programs are central to the project's scientific direction.
Full details on the grant's scope, timeline, and specific research objectives were not disclosed in the initial announcement. Continue reading at GlobeNewswire - Mergers And Acquisitions.
